ASIA RESEARCH & INNOVATION ALLIANCE LIMITED

The ICP - Innovators Commercialization Program, led by Asia Research & Innovation Alliance (ARIA) Institute of Healthtech Excellence in collaboration with National University Hospital of Singapore (NUHS) - Centre for Innovation in Healthcare (CIH), helps innovators accelerate product validation and expansion into Singapore. A global team of healthcare professionals and clinicians offers clinical validation and venture building support over a 6-month program. Upon completion, innovators can access venture investment of up to USD1,000,000. Benefits include venture funding, establishment of a global HQ in Singapore with regulatory incentives, fast track to clinical adoption and trials, networking with the largest medtech companies in the world, and access to a global committee of medical industry professionals. The program focuses on improving users' lifespans and quality of life, enabling seamless delivery of high-quality healthcare, digitalizing hospital systems, and enhancing women's and children's health outcomes. The program is structured into three phases: clinical validation, product activation, and venture funding and scale-up. Eligibility criteria include prototypes development, patent approval or pending approval, obtained preliminary clinical trial data, and business plan development. Apply by sending a 1-slide business plan to connect@ariainstitute.org or through the website

Headquartered in Singapore, ARIA (Asia Research & Innovation Alliance) is an independent non-profit organization dedicated to leveraging technology for positive ESG (Environmental, Social, Governance) impact in emerging countries. We enable digital transformation of traditional industries to e-economies through innovative solutions, training, and implementation. As a leading research and innovation think tank, we collaborate with top global universities, research institutes, and industry leaders to drive real-world impact.